Miriam Ben-Harush

認定:
所在地：イスラエル, ハイファ
クリニック：
5.0
Rambam Medical Center
Prof. Myriam Ben Arush is the Director of the Pediatric Division at Ruth Rappaport Children’s Hospital within Rambam Medical Center. She specializes in pediatric oncology and bone marrow transplantation. The World Medical Association recognized her as one of the world's most caring doctors.
Specialization and Clinical Focus

Prof. Ben Arush treats childhood cancers using therapeutic techniques. Her clinical work revolves around bone marrow transplantation and pediatric hematology. She treats a variety of conditions, including:
- Sarcoma and Ewing's sarcoma
- Neuroblastoma and Nephroblastoma (Wilms tumor)
- Osteosarcoma and Rhabdomyosarcoma
- Retinoblastoma
The doctor performs procedures such as chemotherapy, immunotherapy, and radiotherapy. She also provides targeted leukemia chemotherapy and radiation for specific solid tumors.

Professional Leadership and Experience

Prof. Ben Arush leads the Department of Pediatric Hematology and Oncology at Rambam Medical Center. She also oversees pediatric care at the Ruth Rappaport Children’s Hospital in Haifa. This role involves supervising oncological treatment for young patients in Israel.

Awards and Recognition

Prof. Ben Arush received international and national honors for her work. These awards include:
- Ministry of Health Prize for outstanding medical work
- Chevalier de la Legion d’Honneur (Knight of the Legion of Honour), France
- World Medical Association Caring Physicians of the World Award
Professional Memberships

The specialist participates in the global oncology research community. Her memberships include:
- Children’s Oncology Group (USA)
- Various European cancer societies
続きを読む

パッケージ価格$3,500

Karen Drumea

所在地：イスラエル, ハイファ
クリニック：
5.0
Rambam Medical Center
Radiotherapy Specialist, Oncologist

パッケージ価格$3,500

Bookimed洞察：イスラエルのトップ免疫療法専門家（2026）

Bookimedはイスラエルの免疫療法リクエスト29件を調整し、2名のトップ評価専門家と協力しています。この表の医師は国際的資格、臨床専門知識、患者の結果に基づいて選ばれています。2026年ランキングは実際の患者ケースとパートナークリニックの現行プログラムからの検証済みデータを使用して形成されています

順位	医師	経験	適合する方	特色	クリニックと所在地	診察

FAQ

これらのFAQはBookimedを通じて医療支援を求める実際の患者からのものです。回答は経験豊富な医療コーディネーターと信頼できるクリニック代表者が行います。

Can patients join clinical trials under the supervision of Israeli immunotherapy doctors?

Patients can join clinical trials under the supervision of Israeli immunotherapy doctors at JCI-accredited centers like Sourasky Medical Center. Leading oncologists serve as principal investigators for global trials. These specialists manage access to experimental treatments like CAR T-cell therapy and tumor-infiltrating lymphocytes for international patients.

Expert supervision: Senior oncologists like Dr. Ari Raphael lead multiple pembrolizumab and cell therapy trials.
Broad eligibility: Trials often accept patients with advanced-stage cancers who meet specific genetic inclusion criteria.
Research leadership: Dr. Irina Stepfansky has managed phase 1-3 clinical trials as a primary researcher.
Specialized access: Centers offer trials for diverse conditions, including sarcoma immunotherapy led by Prof. Ofer Merimsky.

Bookimed Expert Insight: Data shows that Israeli oncology leadership often holds dual roles in international research bodies like ESMO and ASCO. For example, Dr. Ari Raphael acts as a Molecular Tumor Board moderator. This high level of integration means patients may access the same immunotherapy protocols found in the US or Europe but with significantly faster enrollment timelines, often within one month.

Patient Consensus: Patients note that Israeli doctors are very welcoming to international participants, even those without local insurance. Many were surprised by how quickly they could start a Phase II trial compared to the long waits in their home countries. They often stay in nearby hotels and find the coordination with medical teams to be direct and efficient.

Who are the leading immunotherapy specialists in Israel?

Leading immunotherapy specialists in Israel include Prof. Dr. Ofer Merimsky and Dr. Ido Wolf at Sourasky Medical Center. These experts hold prestigious European Society for Medical Oncology (ESMO) roles. They lead advanced clinical trials for melanoma, sarcoma, and lung cancer using modern genomic profiling.

Prof. Ofer Merimsky: Leads sarcoma research at Sourasky Medical Center with over 25 years of experience.
Dr. Ari Raphael: Principal investigator for immunotherapy trials specializing in T-cell sequencing and liquid biopsies.
Dr. Dvora Blumental: Directs neuro-oncology immunotherapy services after training at Memorial Sloan-Kettering Cancer Center.
Dr. David Sarid: Senior oncologist at Sourasky with specialized cancer urology training from Oxford University.

Bookimed Expert Insight: Data shows a strong trend of specialization within immunotherapy in Israel. For example, Dr. Ari Raphael focuses on genomic profiling for lung cancer at Sourasky. Meanwhile, Dr. Sonnenblick Amir specializes in Keytruda for breast cancer. Families seeking pediatric care often choose Dr. Dror Levin, who trained at Italy's top bone oncology center. Consultations with these experts typically range from $750 to $1,050.

Patient Consensus: Patients note that Israeli centers offer much faster access to clinical trials than other countries. Many were surprised by the multidisciplinary approach where teams of specialists collaborate on one case. Those traveling to Jerusalem or Tel Aviv feel more involved in their treatment decisions because of the clear communication from the medical staff.

How do Israeli immunotherapy doctors determine who is a good candidate for treatment?

Israeli immunotherapy doctors identify candidates through molecular biomarker testing and advanced genomic profiling. Specialists use next-generation sequencing to find mutations like MSI-H or high tumor mutational burden. They also assess physical fitness using the ECOG scale to confirm a patient can tolerate intensive treatment.

Molecular testing: Doctors measure PD-L1 protein levels to predict drug responses accurately.
Genomic profiling: Surgeons use NGS panels to identify specific actionable genetic mutations.
Performance status: Candidates typically need an ECOG score under 2 for eligibility.
Treatment history: Eligibility often requires failing one or two prior standard therapy lines.

Bookimed Expert Insight: Israeli oncology centers prioritize rapid diagnostics alongside leading researchers like Dr. Ari Raphael at Sourasky Medical Center. He moderates the Molecular Tumor Board and utilizes liquid biopsies to monitor T-cell responses. This integration of real-time genomic data allows doctors to approve immunotherapy for complex cases faster than many other international facilities.

Patient Consensus: Patients note that doctors require thorough bloodwork and PET/CT scans before starting any therapy. Many found that having high PD-L1 levels or specific mutations was the key to getting treatment approval. They often feel relieved by how quickly tumor sequencing results come back in Israel.

What medical reports do Israeli immunotherapy doctors require before a consultation?

Israeli immunotherapy doctors require a detailed medical dossier to determine eligibility for advanced biologics. Patients must provide pathology reports, recent PET-CT or MRI scans (DICOM format), and documented treatment history in English. These records help specialists like Dr. Ido Wolf evaluate tumor markers before recommending specific immunotherapy protocols.

Pathology reports: Original biopsy results including histology and mandatory biomarker status (PD-L1, MSI, TMB).
Imaging files: Decoded reports and original discs for recent CT, PET-CT, or MRI scans.
Treatment summary: Chronological history of previous chemotherapy, radiation dosages, and surgical operation summaries.
Laboratory results: Recent complete blood count and biochemical profiles for kidney and liver function.

Bookimed Expert Insight: While basic pathology is standard, Israeli specialists like Dr. Ari Raphael at Sourasky Medical Center prioritize genomic profiling and liquid biopsy data. Our data shows that submitting MSI-high or dMMR status from NGS testing significantly speeds up the consultation approval process. Patients should also prepare to send original pathological blocks if requested for local laboratory verification.

Patient Consensus: Patients note it is important to have all files translated into English well in advance. Many were surprised that doctors required complete PDF submissions via secure portals at least two weeks before the meeting. They say having a clear log of how they responded to past chemo made the initial talk much more productive.

Do Israeli immunotherapy doctors offer access to clinical trials?

Israeli immunotherapy doctors provide extensive access to clinical trials for advanced cancer care. Specialists at centers like Sourasky Medical Center (Ichilov) serve as principal investigators for phase 1-3 trials. These studies evaluate next-generation therapies like pembrolizumab, TIL-cell therapy, and personalized cancer vaccines.

Specialized researchers: Dr. Irina Stepfansky leads clinical trials with 20+ years of oncology research experience.
Global collaborations: Prof. Ofer Merimsky conducts immunotherapy research in partnership with the Weizmann Institute.
Advanced trial types: Dr. Ari Raphael leads trials for thoracic malignancies using intra-tumoral mRNA therapies.
Diverse cancer focus: Trials cover melanoma, lung cancer, sarcoma, and complex hematologic malignancies like leukemia.

Bookimed Expert Insight: Data shows that top Israeli oncologists often hold dual roles as hospital department heads and principal investigators for global pharmaceutical trials. For example, Dr. Ari Raphael at Sourasky Medical Center (Ichilov) manages pharmaceutical phase I-III studies while moderating molecular tumor boards. This dual expertise allows them to match patients with specific trials based on complex genomic profiling and liquid biopsy results.

Patient Consensus: Patients note that it is vital to ask about trials early because eligibility can change as the disease progresses. Many were surprised to find they could access international studies from companies like Merck or Roche in Tel Aviv. They often find that private consultations, starting from $750 with experts like Dr. Irina Stepfansky, help speed up the eligibility review process.

Can I start with a remote consultation before traveling to Israel?

You can start your immunotherapy journey with a remote consultation before traveling to Israel. This step allows top oncologists to review your medical records and confirm if advanced treatments like Keytruda or specialized protocols are suitable for your specific diagnosis.

Expert document review: Senior oncologists analyze your scans and pathology reports before you travel.
Treatment eligibility: Doctors determine if you qualify for specific immunotherapy or clinical trials.
Travel readiness: Specialists assess if you are physically fit for international air travel.
Personalized planning: Receive a preliminary treatment strategy to organize your stay in Tel Aviv.

Bookimed Expert Insight: Data shows that choosing a doctor with a dual background in research and clinical practice, like Dr. Irina Stepfansky or Dr. Ofer Merimsky at Sourasky Medical Center, provides a significant advantage. These specialists often lead phase I-III clinical trials, meaning they can offer insights into emerging immunotherapy protocols during your remote session that may not be available in standard hospital settings. Consulting with a specialist who holds a consultation for approximately $750 to $950 can save you from unnecessary travel if your case requires a different therapeutic approach.

Patient Consensus: Patients mention that a video call with their doctor made them feel much more at ease before flying. They noted it was helpful to have a clear plan and a familiar face waiting for them at the clinic.

ハイファで最高の免疫療法医師 - トップ2名の医師

イスラエルの3名のトップ免疫療法専門家から見積もりを取得

医師サービスで最良価格の国を選択

Miriam Ben-Harush

Specialization and Clinical Focus

Professional Leadership and Experience

Awards and Recognition

Professional Memberships